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Background: In 2005, the model of end-stage liver disease (MELD)-based allocation system was
adopted to assess potential liver transplant (LT) recipients in Argentina. The aim of the present study was
to revise the activity of the MELD Exception Experts Committee.
Methods: Between 2005 and 2009, 1623 patients were listed for LT. Regulation provides extra-MELD
points for amyloidosis, hepatopulmonary syndrome (HPS) and T2 hepatocellular carcinoma (T2 HCC).
Centres could also request priority for other situations. Using a prospective database, we identified
patients in whom priority points were requested. Pathology reports of explanted livers were analysed for
patients with T2 HCC.
Results: From 234 out of 1623 (14.4%) requests, the overall approval rate was 60.2% including: 2
amyloidosis, 6 HPS, 111 T2 HCC and 22 non-regulated situations. Of the 111 patients with T2 HCC, 6 died
(5.4%), 8 had tumour progression (7.2%), 94 were transplanted (84.2%) and 3 are still waiting. An explants
correlation showed that presumed diagnosis of T2HCC was incorrect in 20/94 (22%) and was correct in
only 41/94 (43%) cases being T1 HCC in 9 and T3 HCC in 23.
Conclusions: MELD exceptions are frequently requested in Argentina. Unfortunately, most receiving
priority points for T2 HCC benefited by medical error or imaging limitations. An intense review process is
urgently needed to maintain equity and justice in the allocation system.
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Introduction
Equitable allocation of donor organs to patients on the waiting
list (WL) is crucial.1 Clearly, if an adequate number of organs
was available, organ allocation would be a much less controver-
sial issue.2 Thus, any effort to optimize organ allocation should
be accompanied by similar intensive efforts to increase the
number of organ donors.3 The ideal allocation system must be
based on equity and justice with objective parameters and trans-
parency.4 In this scenario, the model for end-stage liver disease
(MELD) score aims to stratify recipients by disease severity
according to a score estimating the 3-month probability of death
on the WL. Although the implementation of the MELD-based
allocation system for liver transplantation has reduced mortality
on the WL in US, this has not been validated in other countries.5
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In Argentina, the first liver transplant was performed in 1988.
After being implemented in US, the MELD allocation system was
adopted in 2005 for LT (liver transplant) candidates. In contrast to
other countries, all patients in Argentina are listed in a ‘unique
national’ waiting list, and thus, there is no regional or LT-centre
allocation of deceased liver organs. On the national liver WL, two
major categories are identified. Emergency candidates are referred
to as having acute graft failure within 7 days post-transplant and
receive top priority on the WL. The remaining elective candidates
are ranked based as a function of their MELD score within a single
national liver transplant waiting list. However, it has been recog-
nized that not all LT candidates benefit from LT because they face
a greater risk of dying from intrinsic liver disease. Thus, for
patients whose disease severity is not adequately reflected by the
MELD score, exceptional MELD points can be submitted to a
national board. This exceptional MELD can be requested for only
a few entities with very strict inclusion criteria determined under
specific regulation, or for other medical conditions. These addi-
tional point requests are revised by a national group of experts.
In the present study, the activity of a national MELD Exceptions
Experts Committee was analysed during a period of almost 4 years
after implementing this novel allocation system using the official
database from the INCUCAI (Instituto Nacional Central Unico
Coordinador de Ablacion e Implante) that represents the national
institute for organ allocation in Argentina. The precision of the
pre-operative staging was also assessed as reported by centres
seeking to receive the increased early HCC stage priority by the
Experts Committee using reported histology from the explanted
livers.
Materials and methods
Between July 2005 and April 2009, a total of 2182 patients were
listed for LT in Argentina: 1773 (81.1%) adult and 409 (18.9%)
paediatric candidates. Among the adult population, 150 patients
were listed under emergency and 1623 patients under elective
status and stratified according to the MELD-based allocation
system. Of all elective patients listed under the MELD system,
laboratory values were regularly updated depending on the
patient’s medical condition or the MELD score as follows: every 7
days for patients with MELD points > 20, every 30 days for MELD
points 15–19, every 3 months for MELD points 11–14 and every
12 months for MELD points  10.
For patients in whom the MELD score was thought to estimate
inaccurately the need for LT, each centre could request priority
points to an Experts Committee that constituted a national peer
review system. With the aim of analysing the activity of this MELD
Exceptions Committee a prospective collected national database
was reviewed to include all adult elective patients (i.e.18 years)
listed for LT in Argentina for whom the Experts Committee
opinion was requested.
This Committee comprises of five liver transplant specialists
(minimum two surgeons and two hepatologists) representing dif-
ferent accredited LT programmes from the country. Every year,
three of them are rotated from other centres. There is no standard
application form for a MELD Exception Committee request. The
application should include a letter signed by the liver transplant
programme director and a signed copy of the laboratory values
and imaging reports. The Committee usually performs the evalu-
ation based on the imaging reports but they can also request the
original scans. Each request must be revised in a blinded fashion
by a minimum of two individuals or with a third person in cases
of disagreement and within 48 h a reply must be sent by the
INCUCAI to the requesting LT centre. In those cases resulting in
a refusal from the Committee, each centre could request a review
but only when new information becames available (i.e. laboratory
values or imaging).
A specific national regulation included few categories that
qualify for various degrees of upgrading of their MELD score such
as patients with familial amyloidotic polyneuropathy (16 points),
hepatopulmonary syndrome with PO2 < 60 mmHg (20 points)
and T2 hepatocellular carcinoma (HCC) defined as 1 tumour of
2–5 cm or 2 or 3 tumours of <3 cm in diameter diagnosed accord-
ing to pre-operative imaging (22 points). Patients who receive
additional priority for HCC must have undergone a comprehen-
sive assessment to evaluate the number and size of the liver
tumours and to rule out any extra-hepatic spread and/or mac-
rovascular involvement. A pre-listing biopsy was not mandatory
but the lesion must fulfill the following imaging criteria. The
assessment of the patient should include two non-invasive criteria
that documents tumour size and number including ultrasound
and contrasted computed tomography or magnetic resonance
imaging of the abdomen and chest CT and bone scan to rule out
metastatic disease. All other patients with HCC including those
with downsized tumors in whom their original presenting tumour
was greater than the T2 stage must be referred to the national
review board.
Centres could request priority points for other clinical condi-
tions not included in this regulation such as refractory ascites,
chronic invalidating encephalopathy, severe pruritus, symptom-
atic polycystic liver disease, recurrent biliary sepsis, refractory
variceal bleeding or others. Each non-established category in the
regulation was considered individually by the Experts Committee
to determine the appropriateness of the requested increase in
priority on the basis of medical evidence from the literature or
experts opinion.
Official reporting of the pathology of the explanted liver is
mandatory in the national regulation only for those patients with
priority points as a result of T2 HCC. To assess the precision of the
pre-operative diagnosis as reported by centres seeking to receive
the increase HCC priority, pathological reports were collected for
denied requests. Data regarding the T stage of the explants were
correlated with pre-operative diagnosis at the transplant centre.
Tumor stage was considered as follows: T1, solitary tumour < 2 cm
in greatest dimension; T2, 1 tumour 2–5 cm or 2 or 3 tumours 
3 cm in diameter; and T3, 1 tumour > 5 cm or >3 with one or more
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>3 cm. Patients without malignancy in the explants or in which all
nodules were entirely necrotic with no pre-operative biopsy con-
firming HCC were counted as T0. Patients without pathological
reports available were counted as TX.
Several adult candidate variables were analysed from the data-
base including age, gender, aetiology of liver disease, MELD score
(i.e. at the time of allocation, drop-out, death or the most recent),
WL time and reasons for removal from the WL (death, tumour
progression or transplantation).
Statistical analysis
Summary data are presented as median (range) or interquartile
range (IQR). Sensitivity, specificity, positive and negative predic-
tive values of the Expert Committee judgment on diagnosis of T2
HCC were computed on the basis of findings at pathological
examination. The differences between groups were tested using
the c2- or Fisher’s exact tests for categorical variables. Statistical
significance was indicated by P-values of less than 0.05. Calcula-
tions were done with SPSS statistical software package (version
13.0; SPSS Inc., Chicago, IL, USA).
Results
During the study period, 1623 patients were listed for LT in the
national WL with a median MELD score of 18 points (Table 1). A
total of 234/1623 (14.4%) requests were presented to the MELD
Exceptions Experts Committee. In five instances, the request was
because of political and non-medical reasons (e.g. paediatric LT
centres asking permission to perform an adult LT) and in the
other 229 cases the application was related to patients having
‘exceptional diagnoses’. In other words, in 229/1623 (14.1%) of the
adult elective candidates, the LT team decided that the calculated
MELD score did not assess properly the requirement for LT and,
therefore, priority points were requested.
In 189/234 cases the requests were presented for patients with
one of the standardized conditions included in the official regu-
lation. However, additional points were adjudicated in only 119
cases (62%): 2 familial amyloidotic polyneuropathy, 6 hepatop-
ulmonary syndrome and 111 presumed T2 HCC. Among the sub-
group of patients with a high suspicion of T2 HCC, 6 patients
died on the WL (mortality rate = 5.4%), 8 patients were removed
because of tumour progression (drop-out rate = 7.2%), 3
patients are still waiting and 94 underwent deceased LT (prob-
ability to be transplant = 84.2%). As the decision to accept or
refuse a MELD exception for HCC was based on pre-transplant
imaging, a whole-liver explant correlation was performed to
assess discrepancy with pre-operative tumor diagnosis and
staging. When 94 pathology reports were reviewed, the diagnosis
of HCC was incorrect in 21/94 (22%) cases and T2 HCC was
confirmed in only 41/94 patients (diagnostic accuracy = 43%).
Pre-operative imaging underestimated tumour extension in 23
cases (T3 stage HCC) but overestimated the tumour size in 9
patients (T1 stage HCC). In the subgroup of patients without
HCC (T0 stage = 21 cases), the pathology report identified one
patient with multiple neuroendocrine tumours, one with mul-
tiple adenomas, one with liver haemangioma, three with necrotic
nodules after trans-arterial chemoembolization and 15 instances
of regenerative nodules.
In 70/189 (37%) patients, the request was denied for those with
presumed T2 HCC. From this subgroup with no priority, 12 died
on the WL (mortality rate = 17.1%), 10 patients dropped-out
(14.2%), 42 underwent LT (probability to transplant = 60%) and
six patients remained on the WL. In comparison with the sub-
group of patients with adjudicated extra-points, these patients
had a similar drop-out rate (P = 0.21) but a significantly higher
mortality on the WL (P < 0.02) with considerably less access to
deceased donor LT (P < 0.001). Pathological reports of the
explanted livers were achieved in 40/42 transplanted candidates.
Interestingly, we found that 18 had no HCC; none had T1 HCC, 11
(26.1%) had T2 HCC and 11 patients had T3 HCC. In other words,
the Experts Committee judgment incorrectly denied requests in
26.1% of the patients in whom the pre-operative imaging detected
T2 HCC.
An explants correlation with the Experts Committee judgment
was undertaken based on the pre-transplant imaging diagnosing
the presence of T2 HCC in all patients where pathological reports
were available (n = 134). We observed that the sensibility of the
opinion from the specialists was 78.8% but the specificity was low
(37.8%). The positive predictive value of all positive approvals
from the Experts Committee adjudicating additional MELD
points for patients with presumed T2 HCC was 43.6% with a
concomitant negative predictive value of 72.5%.
Pathological reports for the explanted livers were correlated
with the LT centre judgment when requesting additional points
for T2 HCC. The LT centre’s diagnostic accuracy rate for T2 HCC
was 38.8% (52/134) such that the priority was requested incor-
rectly most of the time. The absence of HCC was observed in
Table 1 Characteristics of elective adult liver transplant candidates
included in the national waiting list
Elective adult
patients (n = 1623)
Age (years) 53.7 (18–74)
Gender (M/F) 926/697
MELD score 18 (6–49)
Waiting list time (days)a 155 (40–519)
Transplanted with a deceased donor LT (%) 665 (41)
Transplanted with a Live donor LT (%) 15 (0.9)
Number of death (%) 240 (14.8)
Number of drop-out from the listb (%) 46 (2.8)
Improve of clinical situation (%) 19 (1.2)
Data expressed as median and range.
aMedian and interquartile range.
bDrop-out from the waiting list because of infection, poor overall status,
neurological disorders or tumour progression.
LT, liver transplant.
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39/134 (29.1%) and over or under staging in the other 43/134
(32%) explants of patients in whom the LT centre asked for the
exceptional request.
There was a request for special consideration in 45 of the 234
patients that were not included in the standard regulation. Five
cases were approved requests because of political reasons and in
another 40 cases the application was related to patients having
‘exceptional diagnoses’ associated with poor clinical conditions or
impaired quality of life. Additional points were adjudicated in
only 17/37 (37%) cases and denied in the others (Tables 2 and 3).
Recurrent cholangitis and post-transplant complications were the
most frequent arguments that the Committee positively consid-
ered to administer extra-MELD points (Table 2). In this subgroup,
most patients were successfully transplanted (13/17, 76.4%), one
died, one improved his clinical condition, one dropped out
because of infectious complications and one patient is still waiting
for a liver.
Inversely, the most frequent outvoted entities by the Experts
Committee among the 23 denied requests not included in the
standard regulation were the presence of hepatorenal syndrome
with ascites and oedema, severe malnutrition and hepatic
encephalopathy alone or associated with intractable gastrointesti-
nal bleeding (Table 3). In the declined group only 12/23 patients
received a LT (52.1%), four died (17.3%), two dropped out and
five remained on the WL.
Discussion
The recently adopted MELD allocation system in Argentina is not
perfect. It is unlikely that a mathematical scoring system would
serve all patients on a LT WL equally well, and for this reason,
MELD allocation policy included a mechanism by which centres
could request increased priority for any patient for whom the
MELD score was thought to inaccurately estimate their need for
LT. We demonstrated that this mechanism has been used in almost
15% of the adult candidates listed for LT in Argentina. The con-
solidation of a national Experts Committee is a strategy that
would permit proper evaluation of each request individually to
provide equity and justice in liver allocation. Interestingly, many
requests were denied and most of them for patients with a pre-
sumed diagnosis of T2 HCC. After almost 4 years of implementa-
tion, this is the first study that reports the activity of the national
Experts Committee but demonstrates disappointing results. This
board of experts had a very low positive predictive value in their
medical decisions with an unacceptable diagnostic accuracy rate
for the evaluation of patients in whom pre-operative imaging
documented the presence of T2 HCC. Unfortunately, based on
pathology reports of the explanted liver, most patients that were
prioritized by the Experts Committee benefited erroneously.
Moreover, most of the LT centre requests for patients with HCC
were for patients that did not have T2 stage HCC. With this sce-
nario of incorrect requests from LT centres and incorrect
upgraded patients by the Experts Committee, an intense and con-
tinuous revision process is urgently needed to maintain equity
and justice of access to the limited pool of cadaveric liver organs.
The adoption of the MELD-based allocation policy dramati-
cally improved organ allocation in Argentina. However, the
absence of Experts Committee activity control and feedback jeop-
ardizes the principles of equity and justice in this mathematical
system. To our knowledge, this is the first study that comprehen-
sively reviewed the activity and accuracy of a national MELD
exception Committee. We consider that with transparency in the
medical decision-making process of this medical expert’s board,
an open interdisciplinary discussion will lead to continual
improvement in organ allocation. There are some shortcomings
in our study that need to be carefully addressed. First, the data
referred for pathological examination was only based on pathol-
ogy reports. We are aware that inter-observer variability could
influence the final diagnosis and staging of these patients. After
this study demonstrating poor explants correlation with pre-
transplant HCC diagnosis, we recommend a centralized revision
of each specimen by a board of experienced pathologists in a blind
fashion to provide equal assessment with uniform analysis.
Second, the use of a new national database has inherent limita-
tions that may affect data quality including problems in the
recording system; changes in personnel related to data entry and
Table 2 List of ‘exceptional diagnoses’ upgraded with extra-MELD
points by the MELD Exceptions Committee (n = 17)
4 Post-transplant delayed hepatic artery thrombosis
4 Recurrent cholangitis
3 Post-transplant recurrent cholangitis
2 Polycystic liver disease
1 Intractable gastrointestinal bleeding + encephalopathy
1 Hepatorenal syndrome with ascites and aedema
1 Intractable pruritus
1 Liver metastases of neuroendocrine tumour of the pancreas
Table 3 List of ‘exceptional diagnoses’ denied by the MELD Excep-




2 Intractable gastrointestinal bleeding (IGB) + encephalopathy
1 Post-transplant recurrent HCC
1 Severe hyponatremia
1 IGB + Encephalopathy + HRSAE
1 Recurrent bacterial cholangitis
1 Refractory ascites
1 Porto-pulmonary Hypertension
1 Recurrent hemangioendotelioma post-transplant
HRSAE, hepatorenal syndrome with ascites and oedema; IGB, intrac-
table gastrointestinal bleeding; HCC, hepatocellular carcinoma.
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erroneously recorded data.6 Third, we could not analyse the utility
of LT in our cohort of patients as post-operative outcome has been
not recorded in the database. Therefore, the survival benefit of the
MELD-base allocation policy and the MELD exception Commit-
tee opinion are unpredictable in Argentina.
MELD allocation policy prioritizes patients based on a defined
endpoint: the risk of death on the WL.6,7 Mortality risk is currently
the most convenient but not necessarily the only endpoint pos-
sible. Only a few entities such as T2 stage HCC, amyloidosis and
hepatopulmonary syndrome have been standardized to receive
additional MELD points under an official regulation. Patients
with T2 stage HCC are prioritized based on the risk of tumour
progression but not by mortality risk on the WL. Unfortunately,
for all other excellent candidates for LT in whom the MELD score
does not estimate the need of LT, allocation rules remain
unclear.4,8–10 In Argentina the most frequent clinical conditions
that triggered a LT centre request were the presence of hepatorenal
syndrome with ascites and aedema, intractable gastrointestinal
bleeding, post-transplant complications and hepatic encephal-
opathy. Ideally, a medical decision of the magnitude of organ
allocation would be made with the highest quality clinical evi-
dence available in the literature. However, strong evidence is
usually not available and many of these conditions occur so infre-
quently that the development of clinical relevant studies will never
be possible. In this context, prioritization policy in Argentina only
relies on the subjective opinion of a minimum of two experts.
Thus, it is unlikely to ensure equity in the decision-making
process among all independent reviewers of the national Com-
mittee. The question about why additional points for patients
with intractable gastrointestinal bleeding or debilitating encepha-
lopathy were sometimes given and others denied remains open
and should be clarified. Other well-defined endpoints that are
measured by objective variables should be developed for such
conditions that were not included in the regulation. Prospective
validation of new mathematical models using objective variables
should be performed before implementing any change in the
current liver allocation policy. International open and constant
re-examination of models and developments are essential for con-
tinuous improvement of organ allocation worldwide.
Our data showed that LT centre opinion considered that the
MELD underestimated the need of LT in nearly 15% of listed
candidates. However, in this critical and competitive scenario for
a scarce available liver pool, the final decision about who will
receive the liver first is based on expert subjective opinions. In
Argentina, 39.7% (93/234) of the requests were denied challeng-
ing the initial expert opinion from the LT centre. Hopefully, this
should not end in a byzantine discussion with continuous dis-
crepancies between transplant specialists about who is more
expert or more objective at the time of organ allocation. A sys-
tematic and mandatory revision of the activity and accuracy of
the Experts Committee that contrasts with an objective alloca-
tion system will provide confidence and transparency to the
whole transplant community.
We investigated the capacity of liver transplant centres and also
of the Experts Committee to properly assess using non-invasive
modalities the existence and extent of HCC prior to transplanta-
tion in the subset of patients with presumed T2 stage HCC that
had available pathological reports. This information is critical to
ensure that patients enlisted for LT really present with such a
cancer, but at the same time, it is relevant to properly establish
whether the patient fits into the accepted criteria for LT with
optimal results, or if the limits are exceeded and the patient should
be denied any priority according to the current policy, or even
excluded from transplantation.11–14 When all requests for addi-
tional points for HCC were correlated with the explanted liver
pathology, we observed very disappointing results. First, the LT
centre diagnostic accuracy rate for T2 HCC was extremely low and
thus, we can confirm that the priority for these patients was most
of the time incorrectly requested. Second, the positive predictive
value of the Experts Committee dictate about the presence T2
HCC was unacceptably low. Third, among LT centre requests and
Expert Committee approval, there were many cases without HCC
(29.1% and 22%, respectively). Perhaps, the absence of a tumour
may mean that the patient was transplanted without the need
and/or given a priority that was not deserved. Fourth, many
patients were under or over-staged in this cohort, and this fact
disables the potential fairness of any priority policy based on
staging. While this false-positive diagnosis should become a major
concern, the data about staging are also provoking. Fifth, in 26.1%
of the patients with a negative dictate from the Experts Commit-
tee this judgment was incorrect and, therefore, these patients were
erroneously penalized with a higher mortality rate and lower
probability to be transplanted. Finally, we can assume that with
the current methodology for diagnosis and staging of HCC, the
patients evaluated for LT are not properly managed.
An important finding was that patients with additional MELD
points by presumed T2 HCC benefited with a higher access to LT
and lower mortality rate. Unfortunately, many errors evidenced by
the pathology reports of the explanted liver put at risk the prin-
ciple of equity and justice that should rule liver allocation. A
considerable amount of patients upgraded by the Experts Com-
mittee had finally no cancer or were over or under staged when
correlated with explanted livers. On one hand, we are aware that
diagnosis and staging of HCC could be improved in Argentina
and therefore, many strategies could be recommended. First,
medical decision of the Experts Committee should be made based
on original copies of the imaging and not on written reports from
the LT center. Second, the non-invasive diagnosis of HCC might
be performed exclusively in centers with state-of-the-art resources
with qualified radiologists.15 Third, the widely accepted non-
invasive criteria used for diagnosing HCC are not included in the
official regulation.16 HCC diagnosis using imaging techniques
should only be made if the dynamic pattern of a nodule detected
within a cirrhotic liver presents intense arterial uptake with con-
trast washout in the venous/ delayed phase.15 Fourth, the creation
of an Experts Radiologist Committee could help to improve the
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low diagnostic accuracy for T2 HCC. Both the lack of common
methodology for liver imaging together with the absence of well-
established imaging criteria are the strongest drawbacks that
translated into a high rate of misdiagnosis. As demonstrated, the
benefit of giving priority with a high accessibility to LT contrasts
with a higher mortality on patients where priority was denied. In
this setting, the best notice for a patient listed for LT is to have a
nodule that fulfills the non-invasive criteria for diagnosis of a T2
stage HCC. These data raise the question whether the priority
points of patient with T2 stage HCC should be reduced to provide
more justice.4 Further multidisciplinary discussion is needed to
reach consensus regarding how to allocate fairly cadaveric livers to
patients with T2 stage HCC.
Donor organ resource is more constrained that most other
heath care resources. Scarce resources can be allocated using three
guiding ethical principles: justice, equity and utility. The MELD
allocation system quantified individual justice based on their
mortality risk.17 However, some authors indicated that the MELD
score predicts accurately which cirrhotic patients will live and
which will die at a given score in only 80–85% of occasions.18
Unfortunately, the justice for these ‘MELD unprotected candi-
dates’ relies only on the arms of few experts using subjective
parameters with a questionable effectiveness. Equity in the MELD
allocation system refers to the quality of being fair or impartial in
the distribution of deceased donor livers. The Experts Committee
evaluates each request individually in a blinded fashion to deter-
minate mortality risk on the WL or sometimes subjective variables
concerning quality of life. But, do hepatologists ask equally MELD
exception requests for all patients in whom the MELD does not
accurately predicts mortality on the WL? Do all patients have
equal access to modern imaging modalities for the screening of
early HCC? Some LT groups may have the necessary expertise and
adequate modern imaging modalities, whereas others need to
improve or modify their clinical management. Currently in
Argentina, the quality of the imaging employed for each centre is
not monitored and the inaccuracy in the judgment of the Experts
Committee represents a major concern. Major efforts should be
made to implement homogenous methods and definitions, as it is
the only way to ensure optimal health care delivery and avoid
unfair enlistment and management of patients considered for
LT.19 Furthermore, as tumour staging plays a critical role in the
points for allocation, it is the key to ensuring that all patients will
be managed according to the same measurements using the same
tools with the same criteria according to a modern technology.
Thus, while the allocation to HCC patients according to stage may
appear to offer a balanced distribution of organs, the wide inter-
center variability in our country jeopardizes equity in organ dis-
tribution. It is the role of the national Ministry of Health and the
INCUCAI to ensure that all patients are staged according to the
same methodology to avoid inequity on the national liver WL.15,19
Finally, utility means that a liver organ would be allocated based
on the overall likelihood of success with much less attention to
individual characteristics of need.1 In a utilitarian system, less ill
candidates might receive more priority because they are not more
likely to have a good outcome. In an appropriate allocation
system, it is clear that equity must be guaranteed to all patients
included on the WL but there should be some balance between
justice and utility in the liver allocation system.
Conclusions
MELD exceptions are frequently requested because of the fact that
a MELD score does not always accurately determinate the need for
LT. Unfortunately, most receiving priority points for T2 HCC were
benefited just by medical mistake or imaging limitations. Further
improvement in imaging modalities and the implementation of
better diagnostic criteria are urgently required to improve diag-
nosis and staging of HCC. The activity of the Experts Committee
and the accuracy of the decision-making process needs continu-
ous overseeing to provide feedback to the transplant community
and to guarantee high standards of excellence for liver allocation
in our country. Periodical internal and external revisions of the
MELD exceptions Committee activity are needed to unsure equity
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